Tomoyoshi Ota

A male Japanese patient in their 30s developed epilepsy in 2017, initially attributed to behavioral anomalies during sleep. Focal epilepsy was diagnosed and controlled with levetiracetam 1500 mg and clonazepam 1 mg until 2019. However, in 2021, the patient began experiencing focal impaired awareness seizures. Owing to the occurrence of seizures approximately once per month, the patient was referred to the epilepsy department of our hospital.